News Releases

March 13, 2017

RTI has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2017 World’s Most Ethical Company®

March 7, 2017

Improving Outcomes for Noncommunicable Diseases in Low- and Middle-Income Countries is a compilation of RTI International and RTI Health Solutions’ work with developing countries to find solutions for growing health threats that affect their well-being and economies. This book presents the...

February 28, 2017

The theme for Rare Disease Day 2017 is research. RTI Health Solutions is proud to be part of the community conducting research to support patients with rare diseases.

February 24, 2017

WorldatWork, a nonprofit human resources (HR) association and compensation authority, awarded RTI International the WorldatWork’s Seal of Distinction for 2017. RTI Health Solutions is a business unit of RTI International. The seal is a unique mark of excellence designed to identify...

February 24, 2017

Patient-reported outcomes (PRO) data is becoming increasingly important in randomized controlled trials. Without complete and transparent reporting, though, readers may have difficulty understanding the methodology used and interpreting trial results. The result is an unfortunate waste of...

February 20, 2017

Cilostazol is a blood clotting inhibitor drug approved in Europe in 2002. It is used to alleviate painful leg cramps during exercise caused by a lack of blood flow. In 2013, the European Medicines Agency recommended labeling changes and requested a drug utilization study to evaluate the impact...

February 15, 2017

The study Assessing the Burden of Treatment-emergent Adverse Events Associated with Atypical Medications, published in BMC Psychiatry, qualitatively assessed the occurrence and burden of side effects from these drugs from both patients’ and physician’s perspectives.

February 13, 2017

Researchers from RTI Health Solutions have published a systematic review in PharmacoEconomics that identified published economic analyses of new oral anticoagulants used to prevent venous thromboembolism after knee and hip replacement. The researchers summarized the modeling techniques employed...

January 26, 2017

Payers worldwide recognize the value of patient reported outcomes (PRO) data in decision making. But what are the characteristics of data that most strongly influence payer decision making? And what impact does that data have on reimbursement decisions and market access?

January 16, 2017

Positive impact. That’s always been the measure of our work. In 2016 we held fast to that standard—delivering sound science, innovative technologies, and evidence-based programs that make a meaningful difference for our clients, and for the communities and people they serve.

January 10, 2017

Treatment patterns for metastatic Colorectal Cancer (mCRC) patients have changed considerably over the last decade since the introduction of new chemotherapies and targeted biologics. These treatments are often administered in various sequences with limited evidence regarding their cost-...

December 20, 2016

When psychiatrists prescribe a drug treatment to a patient, they monitor how well that treatment is working. Scales designed to measure symptoms of specific diagnoses include threshold levels that reflect a minimum clinically important difference (MCID).

December 12, 2016

This webinar will explore the trends in PRO-related product labeling and highlight some key observations found during the review. It will cover what you need to know as you gather evidence about your product, and answer your questions about PRO labeling strategy.

December 5, 2016

Despite an increase in the number of new drugs approved by the US FDA and the increased focus on patient-centered drug development, a recent review showed that the percentage of new drug approvals by the FDA with PRO labeling has declined from about 24% during the period 2006-2010 to 16% between...

December 1, 2016

A well-created budget impact analysis (BIA) can help accurately estimate the potential spend on a new health care treatment. A poorly prepared or missing BIA can lead to disaster.

November 22, 2016

In the face of a growing focus on value and cost effectiveness, authors Stephanie Earnshaw, Nadia Demarteau, and Baudouin Standaert have written a chapter in the newly released book, The Future of Health Economics that introduces innovative new ways to evaluate information for making health care...

November 18, 2016

Infographic. As cost-containment pressures intensify, clinical trial safety and efficacy data alone are no longer adequate to meet the needs of health care decision makers—driving a need for real-world data to demonstrate value of treatments.

November 2, 2016

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its Initiative on US Value Assessment Frameworks Stakeholder Conference, in Washington, DC, USA on September 23, 2016. The one-day meeting was designed to convene stakeholders across all segments of health care to...

October 21, 2016

Psychiatrists and other clinicians should be cautious about allowing patients' genetic information to carry unnecessary weight in their clinical decision making, according to a study published in Value in Health. RTI Health Solutions Senior Research Economist, Marco Boeri, co-authored a study...

October 21, 2016

RTI Health Solutions joins in supporting World Psoriasis Day. This year’s theme is Breaking Barriers for People with Psoriasis. Our researchers are proud to contribute quality research towards helping those with psoriasis gain effective treatments - treatments that can help give patients a...

October 20, 2016

Plaque psoriasis is an inflammatory, chronic skin disease that can have serious negative effects on a patient’s quality of life. Along with physical symptoms, patients report feeling distressed, anxious, depressed, or even suicidal. A study published today in the British Journal of Dermatology...

October 18, 2016

RTI Health Solutions, a business unit of RTI International will join a collaborative led by the Medical Device Innovation Consortium (MDIC) that will work with Parkinson’s patients to determine the benefit and risk tradeoffs they are willing to make for a potential new therapy, and use that...

October 18, 2016

Deepen your understanding of current topics with one of these workshops led by our experts

October 13, 2016

The occurrence of missing PRO data in oncology studies is commonplace. Faulty assumptions about the reasons for the missing data often lead to inadequate analysis and false conclusions.

October 12, 2016

Health-related quality of life (HRQL) is increasingly viewed as a significant endpoint in oncology trials. It’s also valuable for informing clinical practice. But current analyses of HRQL are often mixed. Standard approaches often fail to take into account the more complex causal pathways...

Pages